Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.

Timeline

Start

2013-05-16

Primary completion

2019-02-02

Completion

2021-01-20

Drugs

Indications